RNC NIC EXAM REVIEW STUDY NOTES
◉ Use of fetal scalp electrode (FSE) in HIV-positive pregnancy.
Answer: Contraindicated (no FSE) regardless of the maternal viral
load.
◉ Delivery guidelines for HIV-positive pregnancy.
Answer: Scheduled Cesarean delivery at 38 weeks if viral load
>1,000 copies/mL.
◉ Breastfeeding recommendation for HIV-positive mothers in the
US.
Answer: Contraindicated; formula feeding is recommended to
prevent postnatal transmission.
◉ Intrapartum medication for HIV-positive mothers with viral load
>400 copies/mL.
Answer: Intravenous Zidovudine (AZT) infusion during labor and
delivery.
◉ Postpartum prophylaxis for infants born to HIV-positive mothers.
Answer: Oral Zidovudine (AZT) initiated within 6 to 12 hours after
birth.
,◉ CD4 count diagnostic for AIDS.
Answer: Less than 200 cells/mm³.
◉ Maternal gonorrhea treatment in pregnancy.
Answer: Ceftriaxone (typically 500 mg IM single dose); co-treat for
chlamydia if not ruled out.
◉ Neonatal prophylaxis for ophthalmia neonatorum (gonorrhea).
Answer: Erythromycin 0.5% ophthalmic ointment applied to both
eyes immediately after birth.
◉ Neonatal treatment for documented gonococcal infection.
Answer: A single dose of Ceftriaxone (25 to 50 mg/kg IV or IM).
◉ Screening recommendation for Chlamydia in pregnancy.
Answer: All pregnant women under 25, and older women at
increased risk, at first prenatal visit.
◉ First-line maternal treatment for Chlamydia in pregnancy.
Answer: Azithromycin 1 g orally in a single dose.
, ◉ Test of cure (TOC) timing for Chlamydia in pregnancy.
Answer: 3 to 4 weeks after completing treatment.
◉ Neonatal complications of untreated maternal Chlamydia.
Answer: Ophthalmia neonatorum (conjunctivitis) and chlamydial
pneumonia.
◉ Treatment for neonatal chlamydial conjunctivitis or pneumonia.
Answer: Oral Erythromycin or oral Azithromycin (topical
prophylaxis is ineffective).
◉ Primary neonatal risk of vertical HPV transmission.
Answer: Recurrent respiratory papillomatosis (RRP) in the child's
larynx.
◉ Recommended route of delivery for maternal HPV warts.
Answer: Vaginal delivery, unless condylomata block the birth canal
or risk massive hemorrhage.
◉ Contraindicated HPV wart treatments during pregnancy.
Answer: Podophyllin, podofilox, and imiquimod (due to potential
teratogenicity).
◉ Use of fetal scalp electrode (FSE) in HIV-positive pregnancy.
Answer: Contraindicated (no FSE) regardless of the maternal viral
load.
◉ Delivery guidelines for HIV-positive pregnancy.
Answer: Scheduled Cesarean delivery at 38 weeks if viral load
>1,000 copies/mL.
◉ Breastfeeding recommendation for HIV-positive mothers in the
US.
Answer: Contraindicated; formula feeding is recommended to
prevent postnatal transmission.
◉ Intrapartum medication for HIV-positive mothers with viral load
>400 copies/mL.
Answer: Intravenous Zidovudine (AZT) infusion during labor and
delivery.
◉ Postpartum prophylaxis for infants born to HIV-positive mothers.
Answer: Oral Zidovudine (AZT) initiated within 6 to 12 hours after
birth.
,◉ CD4 count diagnostic for AIDS.
Answer: Less than 200 cells/mm³.
◉ Maternal gonorrhea treatment in pregnancy.
Answer: Ceftriaxone (typically 500 mg IM single dose); co-treat for
chlamydia if not ruled out.
◉ Neonatal prophylaxis for ophthalmia neonatorum (gonorrhea).
Answer: Erythromycin 0.5% ophthalmic ointment applied to both
eyes immediately after birth.
◉ Neonatal treatment for documented gonococcal infection.
Answer: A single dose of Ceftriaxone (25 to 50 mg/kg IV or IM).
◉ Screening recommendation for Chlamydia in pregnancy.
Answer: All pregnant women under 25, and older women at
increased risk, at first prenatal visit.
◉ First-line maternal treatment for Chlamydia in pregnancy.
Answer: Azithromycin 1 g orally in a single dose.
, ◉ Test of cure (TOC) timing for Chlamydia in pregnancy.
Answer: 3 to 4 weeks after completing treatment.
◉ Neonatal complications of untreated maternal Chlamydia.
Answer: Ophthalmia neonatorum (conjunctivitis) and chlamydial
pneumonia.
◉ Treatment for neonatal chlamydial conjunctivitis or pneumonia.
Answer: Oral Erythromycin or oral Azithromycin (topical
prophylaxis is ineffective).
◉ Primary neonatal risk of vertical HPV transmission.
Answer: Recurrent respiratory papillomatosis (RRP) in the child's
larynx.
◉ Recommended route of delivery for maternal HPV warts.
Answer: Vaginal delivery, unless condylomata block the birth canal
or risk massive hemorrhage.
◉ Contraindicated HPV wart treatments during pregnancy.
Answer: Podophyllin, podofilox, and imiquimod (due to potential
teratogenicity).
